Clinical practice guidelines for rare diseases: The orphanet database

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Pavan, Sonia ^a   Rommel, Kathrin ^b   Marquina, María Elena Mateo ^c   Höhn, Sophie ^a   Lanneau, Valérie ^a   Rath, Ana ^a  

^a INSERM   (France)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; DATA ANALYSIS; DATA BASE; HEMATOLOGIC DISEASE; HUMAN; INFORMATION DISSEMINATION; MALIGNANT NEOPLASM; MARFAN SYNDROME; MEDICAL INFORMATION; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PREVALENCE; PUBLICATION; QUALITY CONTROL; RARE DISEASE; WEB BROWSER; FACTUAL DATABASE; INTERNET;

DATABASES, FACTUAL; HUMANS; INTERNET; PRACTICE GUIDELINES AS TOPIC; RARE DISEASES;

EID: 85009959822     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0170365     Document Type: Article

References (47)

1. Field MJ and Lohr KN (eds.). Clinical practice guidelines: directions for a new program, Institute of Medicine. National Academy Press, Washington, DC. 1990.
2. Alonso-Coello P, Irfan A, Solà I, Gich I, Delgado-Noguera M, Rigau D, et al. The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies. Qual Saf Health Care. 2010; 19(6): e58. doi: 10.1136/qshc.2010.042077 PMID: 21127089
3. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. http://eur-lex.europa.eu/legal-content/CS/ALL/?uri=URISERV:l21167. Accessed 10 Dec 2015.
4. Kirschner J, Rodger S, Vry J, Gramsch K, Lochmüller H, Bushby K. How reference networks develop, implement, and monitor guidelines. Orphanet J Rare Dis. 2012; 7(Suppl 2): A14-A14.
5. Sejersen T, Del Giovane C, Filippini G, Leo CG, Meerpohl JJ, Mincarone P, et al. Methodology for production of best practice guidelines for rare diseases. Rare Dis Orphan Drugs. 2014; 1(1):10-19.
6. Henter JI, Gavhed D, Bergsten E, Horne AC, Trottestam H. Clinical guidelines and practices: examples from international collaboration in clinical practice. Rare Dis Orphan Drugs. 2014; S1: OP-14.
7. Rodwell C and Aymé S. (eds.). Report on the State of the Art of Rare Disease Activities in Europe, Part V: Activities of member states and other European countries in the field of rare diseases. July 2014. http://www.eucerd.eu/upload/file/Reports/2014ReportStateofArtRDActivitiesV.pdf. 2014. Accessed 10 Dec 2015.
8. Beales DL. Beyond Horses to Zebras: Sicca Syndrome. J Hosp Librariansh. 2011; 11(4): 311-324.
9. Guidelines International Network (G-I-N). http://www.g-i-n.net/. Accessed 19 Jan 2016.
10. National Guideline Clearing house (NGC). https://www.guideline.gov/. Accessed 19 Jan 2016.
11. National Institute for Health and Care Excellence (NICE) guidance. https://www.nice.org.uk/guidance/ published. Accessed 19 Jan 2016.
12. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF) leitlinen. http://www.awmf.org/leitlinien.html. Accessed 10 Dec 2015.
13. Hilton Boon M, Ritchie K, Manson J. Improving the retrieval and dissemination of rare disease guidelines and research recommendations: a RARE-Bestpractices initiative. Rare Dis Orphan Drugs. 2014; 1(1): 20-29.
14. Ansari S, Rashidian A. Guidelines for guidelines: are they up to the task? A comparative assessment of clinical practice guideline development handbooks. PLoS One. 2012; 7(11): e49864. doi: 10.1371/ journal.pone.0049864 PMID: 23189167
15. Vlayen J, Aertgeerts B, Hannes K, Sermeus W, Ramaekers D. A systematic review of appraisal tools for clinical practice guidelines: multiple similarities and one common deficit. Int J Qual Health Care. 2005; 17(3): 235-42. doi: 10.1093/intqhc/mzi027 PMID: 15743883
16. AGREE collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care. 2003; 12(1): 18-23. doi: 10.1136/qhc.12.1.18 PMID: 12571340
17. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010; 182(18): E839-42. doi: 10.1503/cmaj.090449 PMID: 20603348
18. Pentheroudakis G, Stahel R, Hansen H, Pavlidis N. Heterogeneity in cancer guidelines: should we eradicate or tolerate? Ann Oncol. 2008; 19(12): 2067-78. doi: 10.1093/annonc/mdn418 PMID: 18662954
19. Turner T, Misso M, Harris C, Green S. Development of evidence-based clinical practice guidelines (CPGs): comparing approaches. Implement Sci. 2008; 3: 45. doi: 10.1186/1748-5908-3-45 PMID: 18954465
20. Institute for Quality and Efficiency in Health Care, IQWiG Reports. What type of evidence is currently being considered in the development of clinical practice guidelines for rare diseases? Executive summary of rapid report V10-01, Version 1.0. 2011.
21. Griffiths P, Strong K, Gardner S, Day R, Harrison C, Bronwyn K, et al. DYSCERNE: developing clinical management guidelines for selected dysmorphic syndromes. Orphanet J Rare Dis. 2010; 5(suppl 1): P20.
22. Kremp O., Professional clinical guidelines for rare diseases: methodology. Orphanet J Rare Dis. 2012; 7(suppl 2): A12.
23. Haute Autorité de Santé (HAS). Méthode d'élaboration des Protocoles nationaux de diagnostic et de soins pour les maladies rares, guide méthodologique. Oct. 2012. http://www.has-sante.fr/portail/jcms/ c-1340205/fr/methode-d-elaboration-des-protocoles-nationaux-de-diagnostic-et-de-soins-pnds. Accessed 19 Jan 2016.
24. Standing Guideline Commission of the Association of Scientific Medical Societies in Germany (AWMF). AWMF Guidance Manual and Rules for Guideline Development, 1st Edition 2012. English version. http://www.awmf.org/leitlinien/awmf-regelwerk.html. Accessed 19 Jan 2016.
25. Scottish Intercollegiate Guidelines Network (SIGN). SIGN 50: a guideline developer's handbook. Edinburgh: SIGN; 2015. http://www.sign.ac.uk. Accessed 8 Sept 2016.
26. Orphanet-Linearization rules for rare diseases, Orphanet procedural document, Reports collection, September 2014. http://www.orpha.net/orphacom/cahiers/docs/GB/Orphanet-linearisation-rules.pdf. Accessed 10 Dec 2015.
27. Bioinformatics & Evolutionary Genomics, VIB/UGent, Belgium. http://bioinformatics.psb.ugent.be/ webtools/Venn/. Accessed 10 Dec 2015.
28. Institut National du cancer. http://www.e-cancer.fr/. Accessed 10 Dec 2015.
29. Nourbakhsh E, Nugent R, Wang H, Cevik C, Nugent K. Medical literature searches: a comparison of PubMed and Google Scholar. Health Info Libr J. 2012; 29(3): 214-22. doi: 10.1111/j.1471-1842.2012. 00992.x PMID: 22925384
30. Shariff SZ, Bejaimal SA, Sontrop JM, Iansavichus AV, Haynes RB, Weir MA, Garg AX. Retrieving clinical evidence: a comparison of PubMed and Google Scholar for quick clinical searches. J Med Internet Res. 2013; 15(8): e164. doi: 10.2196/jmir.2624 PMID: 23948488
31. Cassis L, Cortès-Saladelafont E, Molero-Luis M, Yubero D, González MJ, Herrero AO, et al. Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders. Orphanet J Rare Dis. 2015; 10(1): 164.
32. Knai C, Brusamento S, Legido-Quigley H, Saliba V, Panteli D, Turk E, et al. Systematic review of the methodological quality of clinical guideline development for the management of chronic disease in Europe. Health Policy. 2012; 107(2-3): 157-67. doi: 10.1016/j.healthpol.2012.06.004 PMID: 22795610
33. Jacobs C, Graham ID, Makarski J, Chassé M, Fergusson D, Hutton B, et al. Clinical practice guidelines and consensus statements in oncology-an assessment of their methodological quality. PLoS One. 2014; 9(10): e110469.
34. Erratum in: PLoS One. 2014; 9(12): e116267. doi: 10.1371/journal.pone. 0110469 PMID: 25329669
35. Taruscio D, Morciano C, Laricchiuta P, Mincarone P, Palazzo F, Leo CG, et al. RARE-Bestpractices: a platform for sharing best practices for the management of rare diseases. Rare Dis Orphan Drugs. 2014; 1(1): 5-8.
36. Zentrales Informationsportal über seltene Erkrankungen (ZIPSE). http://www.portal-se.de/startseite. html. Accessed 19 Jan 2016.
37. The European Parliament and the Council of the European Union. Regulation (EU) No 282/2014 of the European Parliament and of the Council of 11 March 2014 on the establishment of a third Programme for the Union's action in the field of health (2014-2020) and repealing Decision No 1350/2007/EC Text with EEA relevance. Official Journal of the European Union. 86; 21.3.2014, 1-13. Available: http://eurlex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L-.2014.086.01.0001.01.ENG. Accessed 19 Jan 2016.
38. Council of the European Union. Council Recommendation of 8 June 2009 on an action in the field of rare diseases. Official Journal of the European Union. 151; 3.7.2009, 7-10. Available: http://eur-lex. europa.eu/legal-content/EN/TXT/?uri=CELEX:32009H0703%2802%29. Accessed 19 Jan 2016.
39. patientINFORM. http://www.patientinform.org/. Accessed 10 Dec 2015.
40. Cordier JF. The expert patient: towards a novel definition. Eur Respir J. 2014; 44(4):853-7. doi: 10. 1183/09031936.00027414 PMID: 25271227
41. Wallerstein N. What is the evidence on effectiveness of empowerment to improve health? Copenhagen, WHO Regional Office for Europe. Health Evidence Network report. 2006. http://www.euro.who.int/en/ data-and-evidence/evidence-informed-policy-making/publications/pre2009/what-is-the-evidence-oneffectiveness-of-empowerment-to-improve-health. Accessed 19 Jan 2016.
42. Orphan Drugs Collection, Lists of medicinal products for rare diseases in Europe, April 2015. http:// www.orpha.net/orphacom/cahiers/docs/GB/list-of-orphan-drugs-in-europe.pdf. 2015. Accessed 19 Jan 2016.
43. European Partnership for Action Against Cancer (EPAAC). http://www.epaac.eu/. Accessed 19 Jan 2016.
44. RARECARENet, Information Network on Rare Cancer. http://www.rarecarenet.eu/rarecarenet/. Accessed 19 Jan 2016.
45. Institut National du cancer. Plan Cancer 2014-2019, guérir et prévenir les cancers: donnons les mêmes chances à tous, partout en France, 2nd Edition, Feb 2014. http://www.e-cancer.fr/Plan-cancer/Plancancer-2014-2019-priorites-et-objectifs. Accessed 19 Jan 2016.
46. Dosquet P. Comité de suivi et de prospective du plan national maladies rares, Evolution des protocoles nationaux de diagnostic et de soins, 19 March 2013. http://www.sante.gouv.fr/IMG/pdf/9-P- DOSQUET-PNDS-19-mars-2013.pdf. Accessed 10 Dec 2015.
47. Rodwell C. and Aymé S. (eds.), Report on the State of the Art of Rare Disease Activities in Europe. Part I: overview of rare disease activities in Europe. July 2014. http://www.eucerd.eu/upload/file/Reports/ 2014ReportStateofArtRDActivities.pdf. 2014. Accessed 10 Dec 2015. 47. 2014 User satisfaction survey of the Orphanet website in English, Orphanet report series, Reports Collection. http://www.orpha.net/orphacom/cahiers/docs/GB/Orphanet-survey2014.pdf. Accessed 10 Dec 2015.